Zhu Jun, Han Tenghui, Zhao Shoujie, Zhu Yejing, Ma Shouzheng, Xu Fenghua, Bai Tingting, Tang Yuxin, Xu Yungang, Liu Lei
Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China.
Department of General Surgery, The Southern Theater Air Force Hospital, Guangzhou, China.
Front Oncol. 2022 Jul 7;12:933210. doi: 10.3389/fonc.2022.933210. eCollection 2022.
Necroptosis is a programmed form of necrotic cell death in regulating cancer ontogenesis, progression, and tumor microenvironment (TME) and could drive tumor-infiltrating cells to release pro-inflammatory cytokines, incurring strong immune responses. Nowadays, there are few identified biomarkers applied in clinical immunotherapy, and it is increasingly recognized that high levels of tumor necroptosis could enhance the response to immunotherapy. However, comprehensive characterization of necroptosis associated with TME and immunotherapy in Hepatocellular carcinoma (HCC) remains unexplored. Here, we computationally characterized necroptosis landscape in HCC samples from TCGA and ICGA cohorts and stratified them into two necroptosis clusters (A or B) with significantly different characteristics in clinical prognosis, immune cell function, and TME-landscapes. Additionally, to further evaluate the necroptosis levels of each sample, we established a novel necroptosis-related gene score (NRGscore). We further investigated the TME, tumor mutational burden (TMB), clinical response to immunotherapy, and chemotherapeutic drug sensitivity of HCC subgroups stratified by the necroptosis landscapes. The NRGscore is robust and highly predictive of HCC clinical outcomes. Further analysis indicated that the high NRGscore group resembles the immune-inflamed phenotype while the low score group is analogous to the immune-exclusion or metabolism phenotype. Additionally, the high NRGscore group is more sensitive to immune checkpoint blockade-based immunotherapy, which was further validated using an external HCC cohort, metastatic melanoma cohort, and advanced urothelial cancer cohort. Besides, the NRGscore was demonstrated as a potential biomarker for chemotherapy, wherein the high NRGscore patients with more tumor stem cell composition could be more sensitive to Cisplatin, Doxorubicin, Paclitaxel-based chemotherapy, and Sorafenib therapy. Collectively, a comprehensive characterization of the necroptosis in HCC suggested its implications for predicting immune infiltration and response to immunotherapy of HCC, providing promising strategies for treatment.
坏死性凋亡是一种程序性坏死性细胞死亡形式,在调节癌症发生、发展和肿瘤微环境(TME)中发挥作用,并且可促使肿瘤浸润细胞释放促炎细胞因子,引发强烈的免疫反应。目前,临床免疫治疗中应用的已鉴定生物标志物较少,人们越来越认识到高水平的肿瘤坏死性凋亡可增强对免疫治疗的反应。然而,肝细胞癌(HCC)中与TME和免疫治疗相关的坏死性凋亡的全面特征仍未被探索。在此,我们通过计算对来自TCGA和ICGA队列的HCC样本中的坏死性凋亡格局进行了表征,并将它们分为两个坏死性凋亡簇(A或B),这两个簇在临床预后、免疫细胞功能和TME格局方面具有显著不同的特征。此外,为了进一步评估每个样本的坏死性凋亡水平,我们建立了一种新坏死性凋亡相关基因评分(NRGscore)。我们进一步研究了由坏死性凋亡格局分层的HCC亚组的TME、肿瘤突变负荷(TMB)、对免疫治疗的临床反应以及化疗药物敏感性。NRGscore强大且能高度预测HCC临床结局。进一步分析表明,高NRGscore组类似于免疫炎症表型,而低评分组类似于免疫排斥或代谢表型。此外,高NRGscore组对基于免疫检查点阻断的免疫治疗更敏感,这在一个外部HCC队列、转移性黑色素瘤队列和晚期尿路上皮癌队列中得到了进一步验证。此外,NRGscore被证明是化疗的潜在生物标志物,其中具有更多肿瘤干细胞组成的高NRGscore患者可能对基于顺铂、阿霉素、紫杉醇的化疗以及索拉非尼治疗更敏感。总体而言,对HCC中坏死性凋亡的全面表征表明其对预测HCC的免疫浸润和对免疫治疗的反应具有重要意义,为治疗提供了有前景的策略。